Systemic therapy for the treatment of endometrial cancer |
| |
| Authors: | Manuela Neri Michele Peiretti Gian Benedetto Melis Bruno Piras Valerio Vallerino Anna Maria Paoletti |
| |
| Institution: | 1. Department of Obstetrics and Gynaecology, Department of Surgical Sciences, University of Cagliari, Monserrato, Italy;2. Maternal Child Department, University Hospital of Cagliari, Monserrato, Italymanu.neri11@hotmail.it https://orcid.org/0000-0002-4731-8230;4. Maternal Child Department, University Hospital of Cagliari, Monserrato, Italyhttps://orcid.org/0000-0001-9758-4257;5. Maternal Child Department, University Hospital of Cagliari, Monserrato, Italyhttps://orcid.org/0000-0002-2260-9277;6. Maternal Child Department, University Hospital of Cagliari, Monserrato, Italyhttps://orcid.org/0000-0001-5609-9925;7. Maternal Child Department, University Hospital of Cagliari, Monserrato, Italyhttps://orcid.org/0000-0002-7933-9757;8. Maternal Child Department, University Hospital of Cagliari, Monserrato, Italyhttps://orcid.org/0000-0001-6644-0509 |
| |
| Abstract: | ABSTRACTIntroduction: Endometrial cancer (EC) is one of the most frequent gynecological cancers worldwide. The gold standard treatment of EC is most certainly surgery and may very well be the only therapy in the early stages of disease. To improve outcomes in non-early EC, adjuvant therapy is often employed but this is not standardized. Adjuvant options can include radiotherapy, chemotherapy or a combination of both. Adjuvant chemotherapy could be indicated in high-risk stage I and II or advanced stage EC. Several clinical trials are ongoing in an attempt to define the optimal adjuvant treatment. Furthermore, chemotherapy is the front-line therapy in advanced unresectable, metastatic or recurrent endometrial cancer.Areas covered: Herein, the authors review the first-line chemotherapy for the treatment of endometrial cancer and provide their expert perspectives on these therapies.Expert opinion: Chemotherapy is fundamental in advanced/recurrent EC. Further evidence is needed to characterize the role of adjuvant chemotherapy. Future studies should consider genomic and molecular heterogeneities to identify even more efficient tailored therapies. |
| |
| Keywords: | Adjuvant therapy chemotherapy endometrial cancer systemic therapies target therapies |
|
|
![ORCID Icon]({"type":"image","src":"/templates/jsp/images/orcid.png"} "ORCID Icon")
https://orcid.org/0000-0002-4731-8230;4. Maternal Child Department, University Hospital of Cagliari, Monserrato, Italy